Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral ceritinib in crizotinib-naive ALK-positive NSCLC
2012-003474-36Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Overall response rate. Started Oct 2012; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-003474-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003474-36.